← Leaderboards
Peter M Tessier
University Of Michigan At Ann Arbor
$7,601,443
Attributed
$10,906,189
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,906,189 · 11
By mechanism
R01$5,535,137 · 4
RF1$2,413,343 · 1
R35$1,506,489 · 1
R21$1,307,894 · 4
R03$143,326 · 1
Top collaborators
- Colin Fred Greineder5 shared
- Ravi S Kane2 shared
- Greg Thurber2 shared
- James J. Moon1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Colin Fred Greineder$2,818,848
- Greg Thurber$4,032,895
- Chelsie Elizabeth Armbruster$5,621,521
- Michael John Lucas$132,058
- Steven Richard Meshnick$14,282,524
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAntibodiesProteinsMediatingSpecificityAffinityNeurodegenerative DisordersS DiseasePreventLinkGenerationsDesignParkinson DiseaseBrainBispecific AntibodiesMouse ModelIn VitroAmino Acid Transport System LBaseIn VivoImmunoglobulin GBlood - Brain Barrier AnatomyBlood-Brain Barrier PenetrationMolecular Conformation
Grant awards (30)
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease$735,235
R01 · FY2025 · AG · contact PI
Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine Depots$623,579
R01 · FY2025 · EB · contact PI
Neuron-specific modulation of gene expression using systemically administered bispecific antibody-ASO conjugates$609,153
R01 · FY2025 · NS
Efficient and Long-lived Brain Delivery of Neutralizing Antibodies Against Eastern Equine Encephalitis Virus for Post-exposure Therapy$240,300
R21 · FY2025 · AI · contact PI
Long-lived Activation of Parenchymal Border Macrophages Using Immunocytokines to Address Aging- and Alzheimerâs Disease-associated Deficits in Cerebrospinal Fluid Dynamics$234,000
R21 · FY2025 · AG · contact PI
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease$94,262
R01 · FY2025 · AG · contact PI
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease$762,048
R01 · FY2024 · AG · contact PI
Neuron-specific modulation of gene expression using systemically administered bispecific antibody-ASO conjugates$618,925
R01 · FY2024 · NS
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates$269,727
R35 · FY2024 · GM · contact PI
Neuronal Silencing of ATXN3 Using Peripherally Administered Antibody/ASO Conjugates That Penetrate the Blood-Brain Barrier$195,000
R21 · FY2024 · NS · contact PI
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease$31,422
R01 · FY2024 · AG · contact PI
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease$721,526
R01 · FY2023 · AG · contact PI
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates$269,727
R35 · FY2023 · GM · contact PI
Neuronal Silencing of ATXN3 Using Peripherally Administered Antibody/ASO Conjugates That Penetrate the Blood-Brain Barrier$234,000
R21 · FY2023 · NS · contact PI
Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern$185,721
R21 · FY2023 · AI · contact PI
Design and Evolution of Polyvalent Domain Antibodies Specific for Tau Aggregates$421,875
RF1 · FY2022 · AG · contact PI
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates$269,727
R35 · FY2022 · GM · contact PI
Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern$218,873
R21 · FY2022 · AI · contact PI
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates$269,727
R35 · FY2021 · GM · contact PI
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates$157,854
R35 · FY2021 · GM · contact PI
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates$269,727
R35 · FY2020 · GM · contact PI
Design and evolution of polyvalent domain antibodies specific for tau aggregates$1,991,468
RF1 · FY2018 · AG · contact PI
Design of Antibody Fragments Specific For Amyloidogenic Aggregates$264,633
R01 · FY2018 · GM · contact PI
Design of Antibody Fragments Specific For Amyloidogenic Aggregates$194,798
R01 · FY2017 · GM · contact PI
Design of antibody fragments specific for amyloidogenic aggregates$79,072
R01 · FY2017 · GM · contact PI
Design of antibody fragments specific for amyloidogenic aggregates$264,072
R01 · FY2016 · GM · contact PI
Design of antibody fragments specific for amyloidogenic aggregates$264,072
R01 · FY2015 · GM · contact PI
Design of antibody fragments specific for amyloidogenic aggregates$272,340
R01 · FY2014 · GM · contact PI
Structural basis of species-specific infectivities of two prion strains$71,663
R03 · FY2010 · NS · contact PI
Structural basis of species-specific infectivities of two prion strains$71,663
R03 · FY2009 · NS · contact PI